Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations
Shah, M. V., Hung, K., Baranwal, A., Kutyna, M. M., Al-Kali, A., Toop, C., Greipp, P., Brown, A., Shah, S., Khanna, S., Ladon, D., Gannamani, V., Chen, D., Begna, K., Price, Z. K., Rud, D., Litzow, M. R., Hogan, W. J., Bardy, P. & Badar, T. & 17 others, , 8 Jul 2025, In: Blood Advances. 9, 13, p. 3370-3380 11 p.Research output: Contribution to journal › Article › peer-review
Open Access12 Link opens in a new tab Citations (Scopus) -
IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer
Robinson, N., Polara, R. & Thomas, D., Dec 2025, In: Signal transduction and targeted therapy. 10, 1, 52.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Citations (Scopus) -
RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm
Kok, C. H., Al-Kali, A., Thomas, D., He, R., Kutyna, M. M., Alkhateeb, H., Lim, K., Saliba, A. N., Toop, C., Matin, A., Scott, H., Gangat, N., Brown, A., Mangaonkar, A., Hahn, C. N., Begna, K., Hung, K., Greipp, P., Hogan, W. J. & Patnaik, M. & 2 others, , 12 Aug 2025, In: Blood Advances. 9, 15, p. 3814-3818 5 p.Research output: Contribution to journal › Letter › peer-review
Open Access1 Link opens in a new tab Citation (Scopus)
Datasets
-
Precision Medicine for Chronic Myelomonocytic Leukaemia in Adults: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling. (PREACH-M: PREcision Approach to CHronic Myelomonocytic Leukaemia)
Thomas, D. (Creator) & Thomas, D. (Distributor), South Australian Health and Medical Research Institute, 31 Jan 2029
DOI: 10.58138/gjz0-hf61
Dataset
Prizes
-
New Horizons for Precision Oncology: Targeting Sub-Clones with Metabolic and Immunological Therapies.
Thomas, D. (Speaker)
2025Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
Durable responses to lenzilumab - azacitidine combination therapy in high risk proliferative CMML with suppression of cbl and ras mutant subclones.
Thomas, D. (Speaker)
18 Jun 2025Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
New Directions in Leukaemia Research
Thomas, D. (Participant)
4 Mar 2024 → 6 Mar 2024Activity: Participating in or organising an event › Organising a conference